EIPM's Second Quarter 2025 External Newsletter
July 09, 2025
Dear Friend of the Englander Institute for Precision Medicine,
Welcome to second quarterly external newsletter of 2025!
Thank you for signing up on our website to receive this newsletter, we hope you enjoy learning more about the important progress we've made towards our mission since the end of March.
Since we know you love science and technology, why not follow us daily on our social media channels and never miss our news, events, awards, and publications: on X/Twitter, Facebook, Instagram, Threads, and Bluesky!
It's been a remarkably productive quarter, with new awards & grants to researchers, new clinical trials initiated, news media coverage of our colleagues, exciting events, and published research in top-tier scientific journals. A sample of this work is highlighted below. 
This important work is only possible because of the financial support we receive from foundations, government agencies, corporate partners, and individual donors. We invite you to consider donating to our mission to advance science and speed new treatments to patients.
Thank you again for your interest in our work!
Sincerely,
Olivier Elemento, Ph.D.
News Coverage & Awards 
A new paper in Nature Methods (see below) by EIPM and Pathology and Laboratory Medicine colleagues was covered by: the Cornell Chronicle on April 14th; the WCM Newsroom on April 11th; Medical Device Network on April 14th; The ASCO Post on April 14th; Business Today on April 14th; and The Organizeron April 16th.
Dr. Manish Shah, together with WCM colleagues Drs. Despina Siolas and Gregory F. Sonnenberg, earned a new 2025 PICI Pilot Grant from the Parker Institute for Cancer Immunotherapy and the Meyer Cancer Center to study, "Gut microbiota control of immune suppression in colorectal cancer liver metastases." 
The Bridge2AI Voice project, a collaboration between the EIPM and the University of South Florida, continues to make news with "USF doctor enters final year of research to see if AI can detect vocal diseases," broadcast by Fox13 Tampa Bay on April 23rd.
"AI, Cancer, and HIV: An interview with Dr. Olivier Elemento," was featured in the May 2025 issue of amfAR INNOVATIONS.
"Reporter battles the odds with cancer. Michael Kaplan, veteran journalist and author, has spent decades telling stories of people who beat impossible odds—at the poker table and in life. But in 2023, his own life took a turn when he was diagnosed with mantle cell lymphoma, a rare and aggressive blood cancer." Learn how Dr. Peter Martin and colleagues successfully treated him." The NY Post, June 14th.
Congratulations to our Clinical Director Dr. Cora N. Sternberg on earning the Translational Cancer Research journal's Outstanding Author Award for her recent paper, "Does circulating DNA tumor fraction add value to prostate-specific antigen in metastatic castration-resistant prostate cancer?"
"FDA expands Illuccix label to include patient selection for RLT in pre-taxane setting. 'This empowers clinicians to make more informed, personalized decisions earlier in the disease course and access life-prolonging targeted radionuclide therapy for more patients with prostate cancer.' said EIPM Member Dr. Scott T. Tagawa in an interview with Urology Times, June 23rd. Similar articles were published in The ASCO Post on June 24th, Oncology News Central on June 24th, Targeted Oncology on June 25th, OncLive on June 26th, and CureToday on June 27th.
Dr. Olivier Elemento's new blog post, "AI in Hematology: From Promise to Practice--Diagnostics, Decision-Making and the Path to Reimbursement," ran in the June 29th edition of OncoDaily. He also has new substack posts: "Engineering Multi-Agent AI Systems," that published on June 19th; and "Dermatology’s Next AI Chapter" that published on June 23rd.
Weill Cornell Medicine's Summer 2025 Impact Magazine contains interesting articles about research by EIPM colleagues. "Improving Efficiency of IVF," highlights a new artificial intelligence-based system developed by Dr. Iman Hajirasouliha that can accurately assess the chromosomal status of in vitro-fertilized embryos using only time-lapse video images. And "Boosting Response to Cancer Therapy," recaps a new Nature Immunology paper by Dr. Vivek Mittal who discovered that activating a specific metabolic pathway makes antitumor CD8 T cells more likely to stay in an immature, stem-like, “precursor” state.
Events
Dr. Bishoy Faltas presented the interim results of his investigator-initiated trial, "Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer (CLONEVO)," at the AACR on April 28th. Dr. Bishoy Faltas provided the following Expert Commentary to UroToday: "Spatial Heterogeneity in Expression of Targets of Antibody-Drug Conjugates in Bladder Cancer," on May 7th; "Outcomes of Neoadjuvant Chemotherapy in Invasive Urothelial Carcinoma" on May 9th; "A Clinical Trial of Adjuvant Nivolumab Following Chemoradiation in Localized Muscle-Invasive Urothelial Cancer," on May 12th; and "Trimodality Therapy Compared to Radical Cystectomy for Muscle-Invasive Bladder Cancer," on May 19th.
Clinical Director Dr. Cora N. Sternberg presented her prostate cancer research, "Unenriched baseline CTC-CIN counts are prognostic of overall survival and imaging-based progression-free survival," at the AACR on April 27th. Dr. Sternberg also delivered a Keynote address [that earned her a standing ovation!] during the International Kidney Cancer Symposium in Amsterdam on May 3rd! 
The EIPM and Meyer Cancer Center's joint 2025 Summer Internship Program began on June 25th! The highly-competitive annual program provides high school and college students with hands-on mentored experiential research experiences related to cancer and precision medicine with the goal to encourage the pursuit of STEM careers. We thank all our mentors for their hard work and dedication to making this another memorable summer, and wish our students a fun and meaningful experience!
Publications
"The Bridge2AI-voice application: initial feasibility study of voice data acquisition through mobile health," was published in Frontiers in Digital Health on April 14th by Alexandros Sigaras andDirector Olivier Elemento, Ph.D., with colleagues. 
"The Use of Artificial Intelligence for Cancer Therapeutic Decision-Making," was published in NEJM AI on April 17th by our Director Olivier Elemento, Ph.D. and Clinical Director Cora N. Sternberg, MD.
"Error-corrected flow-based sequencing at whole-genome scale and its application to circulating cell-free DNA profiling," was published in Nature Methods on April 11th by our Chief Research Officer Dr. Bishoy Faltas, with EIPM colleagues Drs. Ashish Saxena, David Wilkes, Nasser K. Altorki, Olivier Elemento, and Michael Sigouros, Jyothi Manohar, Abigail King, John Otilano; and Pathology and Laboratory Medicine & EIPM colleagues Drs. Giorgio Inghirami and Juan Miguel Mosquera. 
"Comprehensive evaluation of phosphoproteomic-based kinase activity inference," was published in Nature Communications on May 22nd by EIPM's Dr. Tomer Yaron and colleagues.
"Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kα potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models," was published in the British Journal of Cancer on May 13th by Dr. Benjamin D. Hopkins and colleagues. 
"Three-dimensional genome landscape of primary human cancers," was published in Nature Genetics on May 12th by Dr. Ekta Khurana and colleagues.
"An atlas of bacterial serine-threonine kinases reveals functional diversity and key distinctions from eukaryotic kinases," was published in Science Signaling on May 6th by Dr. Tomer M. Yaron-Barir and colleagues. 
"Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation," was published in Cancer Cell on May 12th by Michael Sigouros and colleagues.
"Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer," was published as a Nature Communications article on July 1st by Michael Sigouros, Jyothi Manohar, Abigail King, and Dr. Juan Miguel Mosquera from the Pathology and Laboratory Medicine department and the EIPM.
"International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors," was published in the June 2025 edition of The Journal of Liquid Biopsy by our Scientific Director Dr. Massimo Cristofanilli and colleagues.
"First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer," was published in The New England Journal of Medicine on June 1st by our Scientific Director Dr. Massimo Cristofanilli. This research generated significant news media coverage by outlets including: NBC News on June 1st; the Weill Cornell Medicine Newsroom on June 13th; Helio on June 1st, and a Cure article on June 3rd.
# # #